Share on LinkedInShare on LinkedIn

ARTICLE · 06 SEPTEMBER 2023

Spotlight On Upcoming Oral Arguments – September 2023

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The following arguments will be available to the public live, both in-person and through online audio streaming.

United StatesIntellectual Property

The following arguments will be available to the public live, both in-person and through online audio streaming. Access information will be available by 9 AM ET each day of argument at: https://cafc.uscourts.gov/home/oral-argument/listen-to-oral-arguments/.

Tuesday, September 5, 2023

Purdue Pharma L.P. v. Collegium Pharmaceuticals, Inc., No. 22-1482, Courtroom 402

Collegium Pharmaceutical ("Collegium") petitioned for post-grant review ("PGR") of Purdue Pharmaceutical's ("Purdue") U.S. Patent No. 9,693,961 ("the '961 patent") concerning a "Pharmaceutical Formulation Containing Gelling Agent" directed to preventing or deterring opioid abuse. The application for the '961 patent was filed in 2016, claiming priority to a 2001 provisional application. Collegium petitioned alleging that the claims in the specification lacked written description under 35 U.S.C. § 112 and were anticipated under 35 U.S.C. § 102 in view of its own patent application, U.S. Pat. App.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from